Navigation Links
Laerdal Medical and Medical Simulation Corporation Partner to Offer Integrated Training Courses for SimMan(R) Patient Simulators
Date:1/26/2010

WAPPINGERS FALLS, N.Y., Jan. 26 /PRNewswire/ -- Laerdal Medical Corporation today announced a new relationship with Medical Simulation Corporation (MSC), the recognized leader in providing full-service simulation training, education and consulting services to the healthcare industry, in which the companies will jointly offer simulation courseware designed to run on Laerdal's SimMan product family.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080325/NYTU018LOGO )

The courses, Moderate Sedation and Sepsis, help healthcare professionals across disciplines learn and develop the necessary skills to sedate patients or identify and treat patients at risk for developing sepsis in a safe, controlled environment that does not involve real patients.

Both courses offer Web-based curricula, simulation workshops, and simulation scenarios using Laerdal SimMan patient simulators. The courses were developed in response to the growing need in hospitals to address patient safety goals and quality initiatives driven by  The Joint Commission, the Agency for Healthcare Research and Quality and the Institute for Healthcare Improvement, among others.

The Moderate Sedation course is based on guidelines developed by The Joint Commission, American Society of Anesthesiologists and American Association of Nurse Anesthetists, and is suitable for any healthcare provider involved in the administration, assessment and monitoring of patients receiving moderate sedation medications. The Joint Commission requires that hospitals seeking to obtain or maintain accreditation have clear policies for administering moderate and deep sedation and that staff members have appropriate credentials.

The Sepsis program focuses on the early identification, treatment and long-term management of patients with sepsis, and is based on guidelines, tools and research from the Surviving Sepsis Campaign and the Institute for Healthcare Improvement. According to the Surviving Sepsis Web site, sepsis strikes an estimated 750,000 people in the U.S. alone, and is the leading cause of death for critically ill patients in this country. Mortality rates are unacceptably high, and the average cost of treating a patient with sepsis is estimated at $50,000.

"Our new relationship with Medical Simulation Corporation enables Laerdal to deliver comprehensive training solutions to healthcare customers looking to increase staff competence and confidence in delivering moderate sedation and treating patients at risk for developing sepsis," said Joseph Pahlow, vice president of sales, Laerdal. "Hospitals nationwide are increasing their focus on enhancing patient safety and reducing risk, and these courses, with the SimMan simulator the scenarios run on, will help them achieve those goals."

About Medical Simulation Corporation

Medical Simulation Corporation (MSC) is the recognized healthcare industry leader in providing full-service simulation training and education services to healthcare personnel, medical societies and medical product manufacturers. MSC's patient safety solutions are designed to strengthen the competence and confidence of nurses, physicians and technologists. Through its network of training platforms, MSC can provide customized training services to any location worldwide. For more information, please visit www.medsimulation.com or call 888-889-5882.

About Laerdal Medical Corporation

Laerdal Medical, one of the world's leading providers of Healthcare Solutions, is dedicated to helping save lives with products and services for Simulation, Airway Management, Immobilization, Basic Life Support, Advanced Life Support, Patient Care, Self-Directed Learning, and Medical Education. Laerdal is pleased to serve all healthcare providers and educators, from the lay rescuer to the medical professional. For more information, visit http://www.laerdal.com or call 877-523-7325.

Contact:  Wendy Troncone, +1-845-297-7770, wendy.troncone@laerdal.com

SOURCE Laerdal Medical Corporation

RELATED LINKS
http://www.laerdal.com
http://www.medsimulation.com

'/>"/>

SOURCE Laerdal Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
Breaking Medicine News(10 mins):